Skip to main content

Market Overview

Sorrento Developed Socazolimab Enters Late-Stage Lung Cancer Study In China


China's regulatory authorities have signed off on Lee's Pharmaceutical Holdings Limited's Phase 3 trial evaluating socazolimab in small-cell lung cancer.

  • Lee Pharma has in-licensed socazolimab from Sorrento Therapeutics Inc (NASDAQ: SRNE) for the greater China territory.
  • The multicenter, randomized, double-blinded, parallel-group trial will combine socazolimab with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
  • The clearance is based on the results from an earlier Phase 1b trial in which socazolimab combined with carboplatin and etoposide showed a promising efficacy and safety profile.
  • Patient recruitment will start in the second quarter of 2021.
  • Socazolimab is a fully human anti-PD-L1 monoclonal antibody identified by Sorrento using its proprietary G-MAB library platform.
  • Price Action: SRNE shares are trading 3.7% higher at $9.21 in the premarket session on the last check Monday.

Related Articles (SRNE)

View Comments and Join the Discussion!

Posted-In: China lung cancerBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at